Project Grant R44CA295355
Award Date
9/23/24
Completion Date
8/31/26
Dollars Obligated
$748K
Federal Agency
National Cancer Institute
Awardee
Pyrojas Inc. (HAVCNK2LFPP4)
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
New York, NY 10014, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Kure Ai Inc. to develop a novel CAR-T cell therapy product targeting the MR1 antigen expressed on the surface of various tumor cells, including acute myeloid leukemia (AML) and glioblastoma. The key objectives are to: 1) assess MR1 expression in primary patient AML and glioblastoma samples, 2) perform mouse efficacy studies using AML and glioblastoma models, and 3)...
This federal Project Grant award of $400,000 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the advancement of next-generation CAR-T cell therapies for renal cell carcinoma (RCC). The award recipient, Cellinfinity Bio Inc., is developing novel CAR-T cell modifications, including a PRDM1 exon 3 knockout and a CTLA-4 cytoplasmic tail fusion, to enhance CAR-T cell efficacy against RCC tumors. The project aims to evaluate the combination of these...
This $399,669 federal Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to establish the feasibility of commercializing a personalized and multi-targeted adoptive T cell therapy (ATCT) for glioblastoma (GBM), the most common and deadly primary brain tumor. The key products or services to be delivered under this grant include: Evaluating the ability of the applicant's Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) platform to...
The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), awarded a $627,272 Project Grant (CFDA 93.395 Cancer Treatment Research) to The Johns Hopkins University to optimize the efficacy of CAR T cells against pancreatic tumors. The goal is to engineer self-propelled, tumor-infiltrating CAR T cells using synthetic cytokine receptors (velocity receptors) that enhance CAR T cell migration speed and tumor infiltration. The researchers plan to test the motility and...
This Project Grant award of $1,271,780.00 from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), supports research to develop small molecule adaptors for programming a universal chimeric antigen receptor (CAR) T cell therapy. The key objectives are to: 1) Develop small molecule adaptors to target the universal CAR to multiple antigens, including tumor cells and immunosuppressive cells; 2) Enhance targeting specificity using chemical switches...
The National Cancer Institute (NCI) awarded a $1,313,806 Project Grant under the Cancer Treatment Research (CFDA 93.395) federal grant program to the Sloan-Kettering Institute for Cancer Research. The grant, awarded on August 13, 2024, supports research to develop and translate CD28 costimulated chimeric antigen receptor (CAR) T cells that target mesothelin, a cancer-associated antigen overexpressed in solid tumors. Key objectives include exploiting IFN-gamma-mediated cytotoxic mechanisms,...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $674,275 in funding to Marker Therapeutics Inc., a small disadvantaged biotechnology company, to conduct a Phase 1 clinical study evaluating the safety and efficacy of their MT-601 multi-tumor associated antigen-specific T-cell therapy in patients with metastatic pancreatic cancer. The study aims to assess the clinical outcomes of combining MT-601 with frontline FOLFIRINOX chemotherapy,...
This $107,948 Project Grant awarded by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) will fund the development of tunable, microenvironment-responsive CAR T cells to enhance the potency and safety of solid tumor CAR T cell therapy, with a focus on ovarian cancer. The research aims to engineer a hypoxia biosensor circuit in primary human T cells to enable targeted CAR expression and cytokine delivery within the tumor microenvironment, thereby improving anti-tumor efficacy...
The National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), has awarded a $195,766 Project Grant (CFDA 93.395 - Cancer Treatment Research) to Yale University to develop a mechano-transduction platform that will enhance chimeric antigen receptor (CAR) T-cell therapies for treating solid tumors. The project aims to engineer force-sensitive coiled-coils that can be genetically encoded into CAR T-cells to measure forces along key immune receptors (Aim 1) and create...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $626,534 in funding to The Medical University of South Carolina to conduct research aimed at understanding how transient endoplasmic reticulum (ER) stress can enhance the anti-tumor function of T cells. The 5-year project, starting on December 1, 2024, will investigate the mechanisms by which ER stress-induced autophagy can improve mitochondrial function, metabolic programming, and...